docetaxel anhydrous has been researched along with prednisolone in 66 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (prednisolone) | Trials (prednisolone) | Recent Studies (post-2010) (prednisolone) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 34,414 | 3,302 | 7,141 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | prednisolone (IC50) |
|---|---|---|---|
| Glucocorticoid receptor | Homo sapiens (human) | 0.0278 | |
| Progesterone receptor | Homo sapiens (human) | 2.08 | |
| Glucocorticoid receptor | Rattus norvegicus (Norway rat) | 0.0565 | |
| Glycine receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 0.016 | |
| Mineralocorticoid receptor | Homo sapiens (human) | 0.0322 | |
| Glycine receptor subunit beta | Rattus norvegicus (Norway rat) | 0.016 | |
| Glycine receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | 0.016 | |
| Glycine receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | 0.016 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.52) | 18.2507 |
| 2000's | 17 (25.76) | 29.6817 |
| 2010's | 37 (56.06) | 24.3611 |
| 2020's | 11 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Etienne, B; Guérin, JC; Nesme, P; Pérol, M; Robinet, G; Vuillermoz, S | 1 |
| Bessa, EH; Lena, H; Paillotin, D; Pérol, M; Robinet, G; Schuller-Lebeau, MP; Taytard, A; Thomas, P; Vergnenègre, A | 1 |
| Ah-See, AK; Chilcott, F; Eremin, O; Gilbert, FJ; Heys, SD; Hutcheon, AW; Miller, ID; Payne, S; Sharp, PF; Smith, IC; Waikar, S; Welch, AE; Whitaker, T | 1 |
| Culine, S; Droz, JP | 1 |
| Ah-See, AK; Eggleton, SP; Eremin, O; Gilbert, FJ; Heys, SD; Hutcheon, AW; Miller, ID; Ogston, KN; Payne, S; Sarkar, TK; Smith, IC; Walker, LG | 1 |
| Eremin, O; Heys, SD; Hutcheon, AW; Miller, ID; Ogston, KN; Payne, S; Sarkar, TK; Smith, I; Walker, LG | 1 |
| Emberton, M; Parker, C | 1 |
| Arlen, PM; Gulley, JL | 1 |
| Azuma, K; Hashine, K; Miura, N; Numata, K; Sumiyoshi, Y | 2 |
| Bloomfield, D; James, ND; Luscombe, C | 1 |
| Birtle, A; Collins, R; Fenwick, E; Light, K; Norman, G; Palmer, S; Riemsma, R; Trowman, R | 1 |
| Dahl, AA; Fosså, SD; Ginman, C; Iversen, JR; Jacobsen, AB; Jacobsen, IN; Overn, S; Sandstad, B; Urnes, T; Veenstra, M | 1 |
| Bracarda, S | 1 |
| Akaza, H; Harabayashi, T; Hoshi, S; Koga, H; Naito, S; Sumiyoshi, Y; Tsukamoto, T | 1 |
| Fosså, SD | 1 |
| Abratt, RP; Bodrogi, I; Federico, MH; Horti, J; Pover, GM; Sanders, N; Stenzl, A; Widmark, A | 1 |
| Ide, H; Kikuchi, E; Kono, H; Miyajima, A; Nagata, H; Nakagawa, K; Nakashima, J; Ohigashi, T; Oya, M | 1 |
| Al'bitskiĭ, IA; Fastovets, SV; Gafanov, RA; Kaprin, AD | 1 |
| Hashine, K; Kusuhara, Y; Miura, N; Numata, K; Shirato, A; Sumiyoshi, Y | 1 |
| Maehana, T; Mizuno, T; Muto, M; Nishiyama, N; Yanase, M | 1 |
| Cormier, L; Eymard, JC; Ghiringhelli, F; Kermarrec, I; Ladoire, S; Martin, E; Michel, F; Mignot, G; Mourey, E; Zanetta, S | 1 |
| Alhasso, A; Ansari, A; Ansari, J; Glaholm, J; Hussain, SA; Mahmood, R | 1 |
| de Bono, JS; Massard, C; Michels, RM; Sartor, O | 1 |
| Kobayashi, M; Nakamura, M; Ohmori, S; Yaguchi, T | 1 |
| Cortesi, E; Gazzaniga, P; Iacovelli, R; Palazzo, A; Procopio, G | 1 |
| Fujisawa, M; Miyake, H; Muramaki, M | 1 |
| Akaza, H; Arai, Y; Fujita, R; Hashine, K; Hoshi, S; Kakehi, Y; Kanayama, HO; Miki, T; Miura, T; Mizokami, A; Nishimura, K; Nonomura, K; Nonomura, N; Ogawa, O; Ozono, S | 1 |
| Perry, CJ; Sundar, S | 1 |
| Joly, F; Lheureux, S | 1 |
| Fujii, R; Hara, I; Inagaki, T; Kohjimoto, Y; Kuramoto, T; Matusmura, N; Nanpo, Y; Nishizawa, S; Sasaki, Y | 1 |
| Adler, AI; Dyer, M; George, E; Rinaldi, F | 1 |
| Attarian, H; Ghadyani, M; Haghighi, S; Rezvani, H | 1 |
| Cheung, FY; Leung, KC; Ngan, RK | 1 |
| Albiges, L; Attard, G; Bianchini, D; De Bono, JS; Fizazi, K; Ileana, E; Loriot, Y; Massard, C; Patrikidou, A; Pezaro, C; Sandhu, S | 1 |
| Akino, H; Aoki, Y; Ishida, H; Ito, H; Kusukawa, N; Ooyama, N; Tanase, K; Yokoyama, O | 1 |
| Akino, H; Inamura, S; Ito, H; Kusukawa, N; Oyama, N; Taga, M; Tsuchiyama, K; Yokoyama, O | 1 |
| Ahn, H; Ahn, JH; Choi, MK; Hong, BS; Hong, JH; Hong, SW; Jeong, IG; Kim, Y; Lee, JL; Lee, KH; Song, C | 1 |
| Antón Aparicio, LM; Batista, N; Castellano, D; Esteban, E; Germà, JR; Luque, R; Maroto, P; Méndez-Vidal, MJ; Pérez-Valderrama, B; Sánchez-Hernández, A | 1 |
| Byun, SS; Hong, SJ; Kheoh, T; Kim, CS; Kwak, C; Lee, HM; Ou, YC; Rhim, HY; Wan, Y; Wu, HC; Wu, TT; Yeh, H; Yu, MK | 1 |
| Akaza, H; Imanaka, K; Nakatani, T; Nishiyama, T; Ozono, S; Satoh, T; Tanabe, K; Terai, A; Uemura, H; Yokomizo, A | 1 |
| Adachi, H; Fukuta, F; Hirose, T; Itoh, N; Kitamura, H; Kunishima, Y; Masumori, N; Matsukawa, M; Miyake, M; Miyao, N; Shigyo, M; Taguchi, K; Takagi, S; Takahashi, A; Yanase, M | 1 |
| Endou, M; Nagamori, S; Takada, S; Tamaki, S | 1 |
| Daugaard, G; Kongsted, P; Lindberg, H; Sengeløv, L; Svane, IM | 1 |
| Collard, O; De Laroche, G; Falk, AT; Fournel, P; Guillot, A; Magné, N; Merrouche, Y; Méry, B; Moriceau, G; Pacaut, C; Trone, JC | 1 |
| Eto, M; Inokuchi, J; Kiyoshima, K; Koga, H; Naito, S; Shiga, KI; Shiota, M; Takeuchi, A; Tatsugami, K; Yamaguchi, A; Yokomizo, A | 1 |
| Kongsted, P; Lindberg, H; Sengeløv, L; Svane, IM | 1 |
| Andronis, L; Barton, D; Beesley, S; Billingham, L; Birtle, A; Brown, J; Chakraborti, P; Collins, S; Goranitis, I; James, N; McLaren, D; O'Sullivan, J; Parker, C; Pirrie, S; Pope, A; Porfiri, E; Russell, M; Staffurth, J; Stanley, A; Wylie, J | 1 |
| Birtle, AJ; Crabb, SJ; Downs, N; Ellis, M; Griffiths, G; Jones, RJ; Khoo, V; Ksiazek, L; Maishman, T; Martin, K; Ratcliffe, I; Thompson, S | 1 |
| Alhasso, A; Carruthers, R; Cascales, A; Dodds, D; Glen, H; Jones, RJ; Lamb, C; Laskey, J; MacLeod, N; Marashi, H; McKay, S; Neilson, S; Rulach, RJ; Russell, JM; Sadoyze, A; Sidek, N; Venugopal, B; Wallace, J; White, L | 1 |
| Burdett, S; Carpenter, JR; Clarke, NW; Fisher, DJ; Fizazi, K; Gravis, G; James, ND; Mason, MD; Parmar, MKB; Rydzewska, LH; Spears, MR; Sweeney, CJ; Sydes, MR; Tierney, JF; Vale, CL; White, IR | 1 |
| Chan, K; Chan, MFT; Chan, T; Cheng, NM; Lai, KM; Lam, D; Law, S; Lee, EKC; Leung, CH; Ng, CF; Poon, DMC; Teoh, JYC | 1 |
| George, DJ | 1 |
| Hiraki, T; Kanazawa, S; Katayama, N; Katsui, K; Kiura, K; Kuroda, M; Maeda, Y; Ogata, T; Toyooka, S; Watanabe, K | 1 |
| Albuquerque, L; Guerreiro, C; Reimão, S | 1 |
| Hu, YC; Jiang, JH; Ma, L; Ma, Q; Wang, KY; Zhang, LL | 1 |
| Bahl, A; Birtle, AJ; Crabb, SJ; Downs, N; Dunkley, D; Elliott, T; Griffiths, G; Jagdev, S; Jones, RJ; Khoo, V; Kumar, S; Light, M; Martin, K; Marwood, E; Northey, J; Robinson, A; Rooney, C; Salinas-Souza, C; Shaw, E; Stephens, C; Sundar, S; Westbury, C; Whitehead, A; Wilding, S | 1 |
| Burgents, J; Chandana, SR; Facchini, G; Fizazi, K; Flaig, TW; Gafanov, R; Kramer, G; Li, B; Petrylak, DP; Piulats, JM; Ratta, R | 1 |
| Pramod, SV; Safriadi, F; Tresnanda, RI | 1 |
| Bratt, O; Carlsson, S; Fransson, P; Karlsson, CT; Kindblom, J; Stranne, J | 1 |
| Celenkoglu, G; Sayin, M | 1 |
| Alekseev, B; Burgents, J; Chiuri, VE; Clarke, NW; Degboe, A; Fléchon, A; Gresty, C; Jassem, J; Jones, R; Kang, J; Kocak, I; Redfern, C; Saad, F; Sala, N; Thiery-Vuillemin, A; Wiechno, P | 1 |
| Åström, L; Attard, G; Boysen, G; Bracarda, S; Chowdhury, S; Esen, A; Feyerabend, S; Gourgioti, G; López-Brea Piqueras, M; Martins, K; Matveev, VB; Merseburger, AS; Senkus, E | 1 |
| Abdel-Aty, H; Alzouebi, M; Amos, CL; Attard, G; Birtle, A; Brawley, C; Brown, LC; Brown, MD; Cathomas, R; Chowdhury, S; Clarke, NW; Cook, A; Cross, W; Das, P; Dearnaley, DP; Diaz-Montana, C; Gale, J; Gilbert, D; Gillessen, S; Gilson, C; Grant, W; Gray, E; Hoyle, A; Jain, Y; James, ND; Jones, C; Jones, RJ; Langley, RE; Malik, Z; Mason, MD; Matheson, D; Millman, R; Montazeri, AH; Murphy, C; Murphy, L; O'Sullivan, JM; Parikh, O; Parkar, N; Parker, CC; Parmar, MKB; Pedley, I; Pezaro, C; Pugh, C; Robinson, A; Rush, H; Russell, JM; Sachdeva, A; Saxby, H; Srihari, N; Sydes, MR; Tanguay, J; Thomas, C; Wagstaff, J; Wylie, J; Zarkar, A | 1 |
11 review(s) available for docetaxel anhydrous and prednisolone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress?
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Paclitaxel; Palliative Care; Prednisolone; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Taxoids | 2000 |
The changing pattern of management for hormone-refractory, metastatic prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Diphosphonates; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Palliative Care; Prednisolone; Prostatic Neoplasms; Spinal Cord Compression; Taxoids; Urologic Diseases | 2006 |
A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Prednisolone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
[Scleroderma-like skin sclerosis induced by docetaxel chemotherapy for hormone refractory prostate cancer: a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prednisolone; Prostatic Neoplasms; Scleroderma, Diffuse; Taxoids | 2010 |
Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Forecasting; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Prednisolone; Prostatic Neoplasms; Quality of Life; Taxoids; Treatment Failure | 2011 |
Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Docetaxel; Humans; Male; Neoplasm Metastasis; Prednisolone; Prostatic Neoplasms; Radioisotopes; Taxoids; Tissue Extracts | 2011 |
Abiraterone acetate in castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Androgen Antagonists; Androstadienes; Clinical Trials as Topic; Docetaxel; Humans; Male; Orchiectomy; Prednisolone; Prostatic Neoplasms; Taxoids | 2012 |
[Antisense oligonucleotide therapy for patients with castration-resistant prostate cancer].
Topics: Castration; Docetaxel; Humans; Male; Oligonucleotides, Antisense; Prednisolone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2011 |
What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Network Meta-Analysis; Prednisolone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid | 2018 |
Ketoconazole for the Treatment of Docetaxel-Naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Systematic Review.
Topics: Adrenal Cortex Hormones; Antifungal Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Hydrocortisone; Ketoconazole; Male; Prednisolone; Prednisone; Progression-Free Survival; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Retrospective Studies | 2021 |
23 trial(s) available for docetaxel anhydrous and prednisolone
| Article | Year |
|---|---|
[Efficacy of docetaxel in non-small cell lung cancer patients previously treated with platinum-containing chemotherapy. French Group of Pneumo-Cancerology].
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diosmin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Prednisolone; Premedication; Taxoids; Time Factors | 2000 |
Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chi-Square Distribution; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Linear Models; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prednisolone; Taxoids; Treatment Outcome; Vincristine | 2002 |
Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prednisolone; Scotland; Survival Analysis; Taxoids; Time Factors; Treatment Outcome; Vincristine | 2002 |
Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Prednisolone; Prostatic Neoplasms; Quality of Life; Taxoids | 2007 |
Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan.
Topics: Aged; Alopecia; Anorexia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Feasibility Studies; Humans; Japan; Leukopenia; Male; Middle Aged; Neutropenia; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2008 |
A randomized phase II trial comparing weekly taxotere plus prednisolone versus prednisolone alone in androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Taxoids | 2008 |
A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Double-Blind Method; Humans; Male; Middle Aged; Piperidines; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Taxoids; Treatment Outcome | 2009 |
[Combined treatment of metastatic hormone-resistant prostate cancer].
Topics: Aged; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Humans; Male; Neoplasms, Hormone-Dependent; Palliative Care; Prednisolone; Prostatic Neoplasms; Radiotherapy, Adjuvant; Survival Analysis; Taxoids; Treatment Outcome | 2009 |
Docetaxel-prednisolone combination therapy for Japanese patients with hormone-refractory prostate cancer: a single institution experience.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Neoplasms, Hormone-Dependent; Prednisolone; Prostatic Neoplasms; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Docetaxel; Humans; Male; Middle Aged; Prednisolone; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Failure; Treatment Outcome | 2010 |
Prolonged treatment with three-weekly docetaxel plus daily prednisolone for metastatic castration-resistant prostate cancer: a multicenter, phase II, open-label, non-comparative, extension study in Japan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Humans; Japan; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Orchiectomy; Prednisolone; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2013 |
Efficacy of taxotere, thalidomide, and prednisolone in patients with hormone-resistant metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Gonadotropin-Releasing Hormone; Humans; Kaplan-Meier Estimate; Male; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Soft Tissue Neoplasms; Taxoids; Thalidomide | 2012 |
Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Infusions, Intravenous; Inhibitory Concentration 50; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Taxoids; Thrombocytopenia; Treatment Outcome | 2014 |
Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisolone; Prostatic Neoplasms, Castration-Resistant; Spain; Taxoids | 2014 |
Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients.
Topics: Aged; Androgens; Androstenes; Antineoplastic Agents; Disease Progression; Docetaxel; Drug Therapy, Combination; Glucocorticoids; Humans; Incidence; Male; Orchiectomy; Prednisolone; Prostatic Neoplasms, Castration-Resistant; Republic of Korea; Survival Rate; Taiwan; Taxoids; Treatment Failure | 2014 |
A phase 2 study of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2014 |
TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Cost-Benefit Analysis; Diphosphonates; Disease-Free Survival; Docetaxel; Humans; Imidazoles; Male; Middle Aged; Prednisolone; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Quality-Adjusted Life Years; Strontium Radioisotopes; Taxoids; Zoledronic Acid | 2016 |
ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Humans; Male; Maximum Tolerated Dose; Middle Aged; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Taxoids | 2017 |
Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Double-Blind Method; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisolone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Time Factors; United Kingdom | 2021 |
KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Docetaxel; Double-Blind Method; Humans; Male; Middle Aged; Multicenter Studies as Topic; Prednisolone; Prednisone; Progression-Free Survival; Prostate; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic | 2021 |
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
Topics: Androgen Antagonists; Androgens; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Double-Blind Method; Humans; Male; Pain; Patient Reported Outcome Measures; Phthalazines; Piperazines; Prednisolone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Testosterone | 2022 |
Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Double-Blind Method; Humans; Male; Neutropenia; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2022 |
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
Topics: Abiraterone Acetate; Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Meta-Analysis as Topic; Prednisolone; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic | 2023 |
32 other study(ies) available for docetaxel anhydrous and prednisolone
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
[Acute diffuse interstitial pneumopathy following docetaxel (Taxotère). Apropos of 2 cases].
Topics: Aged; Alveolitis, Extrinsic Allergic; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Hypersensitivity; Glucocorticoids; Humans; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Male; Paclitaxel; Prednisolone; Pulmonary Edema; Taxoids | 1998 |
Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biopsy; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorodeoxyglucose F18; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Paclitaxel; Prednisolone; Radiopharmaceuticals; Sensitivity and Specificity; Taxoids; Tomography, Emission-Computed; Vincristine | 2000 |
Prolonging survival in prostate cancer: chemotherapy will have an important role.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Mitoxantrone; Prednisolone; Prostatic Neoplasms; Taxoids | 2005 |
Docetaxel-based regimens, the standard of care for metastatic androgen-insensitive prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Mitoxantrone; Prednisolone; Prostatic Neoplasms; Taxoids | 2005 |
[A case of hormone-refractory prostate cancer (HRPC) with tumor fever responding to docetaxel plus prednisolone therapy].
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Fever; Gonadotropin-Releasing Hormone; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Neoplasm Invasiveness; Prednisolone; Prostatic Neoplasms; Taxoids; Urinary Bladder Neoplasms | 2006 |
Editorial comment on: Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prednisolone; Prostatic Neoplasms; Taxoids | 2007 |
The preliminary results of docetaxel-prednisolone combination therapy for the Japanese patients with hormone-refractory prostate cancer.
Topics: Administration, Oral; Aged; Ambulatory Care; Docetaxel; Drug Administration Schedule; Drug Therapy, Combination; Fatigue; Feasibility Studies; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2007 |
Docetaxel in combination with prednisolone for hormone refractory prostate cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Humans; Male; Neoplasms, Hormone-Dependent; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids; Treatment Outcome | 2010 |
Primary cutaneous nocardiosis caused by Nocardia beijingensis in an immunocompromised patient with chemotherapy for advanced prostate cancer.
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Fluoroquinolones; Humans; Immunocompromised Host; Male; Nocardia; Nocardia Infections; Prednisolone; Prostatic Neoplasms; Severity of Illness Index; Taxoids; Treatment Outcome | 2012 |
Cabazitaxel rechallenge at prostate-specific antigen relapse after previous cabazitaxel and docetaxel chemotherapy: case report.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Male; Neoplasm Recurrence, Local; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2012 |
[Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Mitoxantrone; Prednisolone; Prostatic Neoplasms; Taxoids | 2012 |
Docetaxel in combination with estramustine and prednisolone for castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Estramustine; Humans; Lymphatic Metastasis; Male; Middle Aged; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2013 |
NICE guidance on abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen.
Topics: Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Castration; Cost-Benefit Analysis; Docetaxel; Drug Costs; Evidence-Based Medicine; Humans; Male; Practice Guidelines as Topic; Prednisolone; Prostatic Neoplasms; Quality-Adjusted Life Years; Taxoids; Terminal Care; Time Factors; Treatment Outcome; United Kingdom | 2012 |
Docetaxel chemotherapy for Chinese patients with castrate-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Disease-Free Survival; Docetaxel; Hong Kong; Humans; Male; Middle Aged; Pain; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids; Tertiary Care Centers; Treatment Outcome | 2013 |
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).
Topics: Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Kallikreins; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Taxoids; Treatment Outcome | 2013 |
[Successful treatment with docetaxel and prednisolone for paxlitaxel and carboplatin-resistant prostate cancer].
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Paclitaxel; Prednisolone; Prostatic Neoplasms; Taxoids | 2013 |
[A case on hemodialysis with castration-resistant prostate cancer which responded to combination chemotherapy with docetaxel and prednisolone].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Humans; Kidney Failure, Chronic; Male; Prednisolone; Prostatic Neoplasms; Renal Dialysis; Taxoids | 2013 |
Efficacy and safety of docetaxel and prednisolone for castration-resistant prostate cancer: a multi-institutional retrospective study in Japan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Docetaxel; Humans; Japan; Male; Medical Records; Middle Aged; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
[Risk factors for predicting severe leukopenia induced by docetaxel plus prednisolone in patients with Castration-Resistant Prostate cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Leukopenia; Male; Middle Aged; Prednisolone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Factors; Taxoids | 2015 |
Low-dose prednisolone in first-line docetaxel for patients with metastatic castration-resistant prostate cancer: is there a clinical benefit?
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Prednisolone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids | 2015 |
Translating Clinical Evidence-Based Medicine into the Real World: Single-Center Experience with Cabazitaxel in Metastatic Prostate Cancer Patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Evidence-Based Medicine; Humans; Kaplan-Meier Estimate; Male; Neoplasm Metastasis; Prednisolone; Prostatic Neoplasms; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2016 |
Co-introduction of a steroid with docetaxel chemotherapy for metastatic castration-resistant prostate cancer affects PSA flare.
Topics: Aged; Antineoplastic Agents; Dexamethasone; Docetaxel; Drug Therapy, Combination; Glucocorticoids; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2016 |
Predictors of Chemotherapy-Induced Toxicity and Treatment Outcomes in Elderly Versus Younger Patients With Metastatic Castration-Resistant Prostate Cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Dose-Response Relationship, Drug; Humans; Kallikreins; L-Lactate Dehydrogenase; Logistic Models; Male; Middle Aged; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2016 |
Real-world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Febrile Neutropenia; Gonadotropin-Releasing Hormone; Hospitalization; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids; Time Factors | 2018 |
A Territory-wide, Multicenter, Age- and Prostate-specific Antigen-matched Study Comparing Chemohormonal Therapy and Hormonal Therapy Alone in Chinese Men With Metastatic Hormone-sensitive Prostate Cancer.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Follow-Up Studies; Geography; Humans; Male; Middle Aged; Prednisolone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate | 2019 |
Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy.
Topics: Abiraterone Acetate; Absorptiometry, Photon; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisolone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid | 2019 |
Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non-small cell lung cancer: Analysis of dose-volume parameters.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Glucocorticoids; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Prednisolone; Radiation Pneumonitis; Retrospective Studies; Withholding Treatment | 2020 |
Radiation recall myelitis following capecitabine: First case report.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Carcinoma; Combined Modality Therapy; Docetaxel; Drug Substitution; Female; Humans; Hyperbaric Oxygenation; Letrozole; Middle Aged; Myelitis; Myositis; Prednisolone; Radiodermatitis; Radiotherapy, Adjuvant; Spinal Cord; Spinal Neoplasms; Thoracic Vertebrae | 2020 |
Efficacy and safety of docetaxel and prednisolone chemotherapy in very elderly men with metastatic castration-resistant prostate cancer (mCRPC) in real world: a single institute experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Docetaxel; Humans; Male; Prednisolone; Prednisone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2021 |
The Swedish national guidelines on prostate cancer, part 2: recurrent, metastatic and castration resistant disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Denosumab; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Orchiectomy; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Sweden; Zoledronic Acid | 2022 |
Comparison of Weekly Low Dose Docetaxel with the Standard Protocol in Hormone-resistant Metastatic Prostate Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Hormones; Humans; Male; Prednisolone; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2022 |